Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Antegenes logo — Innovative genetic tests for cancer risks with recommendatio...

Antegenes

Innovative genetic tests for cancer risks with recommendations for prevention and early detection.

Founded 2018 Estonia Estonia 16 employees Seed Total: $3.05M Biotechnology, Health Care

General Information

Company Name Antegenes
Founded Year 2018
Location Estonia Estonia
Employees 16
Industries Biotechnology, Health Care
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Antegenes. To contact Antegenes, visit antegenes.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Antegenes compare?

A PDF of Antegenes and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Antegenes soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Antegenes

Antegenes is a healthcare technology startup founded in 2018 and based in Estonia. The company focuses on developing and implementing innovative genetic tests utilizing polygenic risk score technology to enable personalized prevention of common cancers. With a slogan of "Innovative genetic tests for cancer risks with recommendations for prevention and early detection," Antegenes aims to revolutionize cancer risk assessment and prevention.

The company recently secured a significant €1.60M investment in a Seed Round at 02 August 2022, backed by notable investors including Timo Rein, Andreas Henn Otsmaa, Peep Vain, and Aare Kurist. This latest investment reaffirms the market's confidence in Antegenes' innovative approach and potential impact on the biotechnology and healthcare industries.

Antegenes' commitment to leveraging genetic testing for personalized cancer prevention aligns with the growing demand for advanced healthcare solutions. Their efforts can not only transform preventive healthcare but also have the potential to drive significant advancements in the biotechnology and health care sectors.

Business keywords: genetic diagnostics, cancer risk assessment, genetic testing, precision medicine, clinical recommendations, cancer prevention

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €700.00K 2
EIT - European Institute of Innovation and Technology, Enterprise Estonia
02 Aug 2022
Seed Round €1.60M 4
Timo Rein, Andreas Henn Otsmaa +2
02 Aug 2022
Pre Seed Round €500.00K -
10 Nov 2021
Angel Round €250.00K -
01 Feb 2018

Antegenes Alternatives & Competitors

View All Alternatives
Antegenes vs
mdxhealth
mdxhealth United States

Molecular Diagnostic Solutions for Prostate Cancer

Post-IPO Equity
262 employees
Biotechnology, Health Care
Antegenes vs
Inbiomotion
Inbiomotion Spain

Perspective from knowledge

Venture round
12 employees
Biotechnology, Health Care
Antegenes vs
Castle Biosciences, Inc.
Castle Biosciences, Inc. United States

Improving health through innovative tests that guide patient care

Post-IPO Equity
744 employees
Biotechnology, Health Care
Also compare with: Antegenes vs 3DMedcare 3DMedcare View all alternatives

FAQ About Antegenes

Innovative genetic tests for cancer risks with recommendations for prevention and early detection.
Antegenes was founded in 2018.
Antegenes is headquartered in Estonia.
Antegenes operates in Biotechnology and Health Care. Its work centres on genetic diagnostics, cancer risk assessment, genetic testing and precision medicine.
Antegenes has approximately 16 employees.
Antegenes has completed 4 funding rounds, raising a total of $3.05M. The latest funding stage is Seed.
Top alternatives and competitors to Antegenes include mdxhealth, Inbiomotion, Castle Biosciences, Inc., Cardio Diagnostics Holdings Inc., Geneoscopy. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Antegenes and mdxhealth are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Antegenes, https://bouncewatch.com/company/antegenes, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes